Kenneth Lin1, John Vickery. 1. Center for Primary Care, Prevention and Clinical Partnerships, Agency for Healthcare Research and Quality, Rockville, Maryland 20850, USA. Kenneth.Lin@ahrq.hhs.gov
Abstract
BACKGROUND: Screening for hepatitis B virus (HBV) infection in pregnant women to identify newborns who will require prophylaxis against perinatal infection is a well-established, evidence-based standard of current medical practice. In 2004, the U.S. Preventive Services Task Force (USPSTF) recommended universal screening of pregnant women for HBV infection at the first prenatal visit. PURPOSE: To search for large, high-quality studies related to hepatitis B screening in pregnancy that have been published since the 2004 USPSTF recommendation. DATA SOURCES: English-language studies indexed in PubMed and the Cochrane Database of Systematic Reviews and published between 1 January 2001 and 5 March 2008. STUDY SELECTION: For benefits of screening and newborn prophylaxis, we included systematic reviews; meta-analyses; and randomized, controlled trials. For harms of screening, we included systematic reviews; meta-analyses; randomized, controlled trials; cohort studies; case-control studies; and case series of large, multisite databases. Abstracts and full articles were independently reviewed for inclusion by both reviewers. DATA EXTRACTION: Data on the benefits of screening, including benefits of hepatitis B immune globulin and hepatitis B vaccine prophylaxis of newborns of hepatitis B surface antigen-positive mothers, were extracted by 1 reviewer. DATA SYNTHESIS: No new studies met inclusion criteria. A 2006 systematic review of randomized, controlled trials found that newborn prophylaxis reduced perinatal transmission of HBV infection; all relevant trials were published in 1996 or earlier. LIMITATION: The focused search strategy, which was restricted to English-language articles, may have missed some smaller studies or new research published in languages other than English. CONCLUSION: No new evidence was found on the benefits or harms of screening for HBV infection in pregnant women. Previously published randomized trials support the 2004 USPSTF recommendation for screening.
BACKGROUND: Screening for hepatitis B virus (HBV) infection in pregnant women to identify newborns who will require prophylaxis against perinatal infection is a well-established, evidence-based standard of current medical practice. In 2004, the U.S. Preventive Services Task Force (USPSTF) recommended universal screening of pregnant women for HBV infection at the first prenatal visit. PURPOSE: To search for large, high-quality studies related to hepatitis B screening in pregnancy that have been published since the 2004 USPSTF recommendation. DATA SOURCES: English-language studies indexed in PubMed and the Cochrane Database of Systematic Reviews and published between 1 January 2001 and 5 March 2008. STUDY SELECTION: For benefits of screening and newborn prophylaxis, we included systematic reviews; meta-analyses; and randomized, controlled trials. For harms of screening, we included systematic reviews; meta-analyses; randomized, controlled trials; cohort studies; case-control studies; and case series of large, multisite databases. Abstracts and full articles were independently reviewed for inclusion by both reviewers. DATA EXTRACTION: Data on the benefits of screening, including benefits of hepatitis B immune globulin and hepatitis B vaccine prophylaxis of newborns of hepatitis B surface antigen-positive mothers, were extracted by 1 reviewer. DATA SYNTHESIS: No new studies met inclusion criteria. A 2006 systematic review of randomized, controlled trials found that newborn prophylaxis reduced perinatal transmission of HBV infection; all relevant trials were published in 1996 or earlier. LIMITATION: The focused search strategy, which was restricted to English-language articles, may have missed some smaller studies or new research published in languages other than English. CONCLUSION: No new evidence was found on the benefits or harms of screening for HBV infection in pregnant women. Previously published randomized trials support the 2004 USPSTF recommendation for screening.
Authors: Allison J Kwong; Matthew S Chang; Ruth E Tuomala; Laura E Riley; Julian N Robinson; Muthoka L Mutinga; Karin L Andersson; Robert S Brown; Emily Oken; Chinweike Ukomadu; Anna E Rutherford Journal: Matern Child Health J Date: 2018-09
Authors: Matthew S Chang; J Frank Wharam; Fang Zhang; Robert F LeCates; Emma Morton-Eggleston; Ruth E Tuomala; Anna E Rutherford; Muthoka L Mutinga; Karin L Andersson; Robert S Brown; Chinweike Ukomadu; Emily Oken Journal: J Clin Gastroenterol Date: 2019 Nov/Dec Impact factor: 3.062
Authors: Matthew S Chang; Kerri Barton; Molly Crockett; Ruth E Tuomala; Anna E Rutherford; Muthoka L Mutinga; Karin L Andersson; Robert S Brown; Emily Oken; Chinweike Ukomadu Journal: J Clin Gastroenterol Date: 2016-07 Impact factor: 3.062
Authors: S K Sarin; M Kumar; G K Lau; Z Abbas; H L Y Chan; C J Chen; D S Chen; H L Chen; P J Chen; R N Chien; A K Dokmeci; Ed Gane; J L Hou; W Jafri; J Jia; J H Kim; C L Lai; H C Lee; S G Lim; C J Liu; S Locarnini; M Al Mahtab; R Mohamed; M Omata; J Park; T Piratvisuth; B C Sharma; J Sollano; F S Wang; L Wei; M F Yuen; S S Zheng; J H Kao Journal: Hepatol Int Date: 2015-11-13 Impact factor: 6.047
Authors: Matthew S Chang; Ruth Tuomala; Anna E Rutherford; Muthoka L Mutinga; Karin L Andersson; Blaire E Burman; Robert S Brown; Emily Oken; Chinweike Ukomadu Journal: Am J Obstet Gynecol Date: 2014-09-30 Impact factor: 8.661